In addition, even though mismatch repair deficiency is rare in pancreatic adenocarcinomas, other molecular lesions, such as ARID1A mutations, may confer immune checkpoint inhibitor sensitivity and could become the basis for synergistic combinations [103]. Here, ARID1A is linked to pancreatic adenocarcinoma.